Infant Bacterial Therapeutics AB (9IB) Stock Statistics & Valuation Metrics
Total Valuation
Infant Bacterial Therapeutics AB has a market cap or net worth of EUR 80.38M. The enterprise value is EUR 834.40M.
- Market Cap
- EUR 80.38M
- Enterprise Value
- EUR 834.40M
Share Statistics
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,018,137
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Infant Bacterial Therapeutics AB’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -58.82%.
- Return on Equity (ROE)
- -0.62
- Return on Assets (ROA)
- -0.40
- Return on Invested Capital (ROIC)
- -58.82%
- Return on Capital Employed (ROCE)
- -0.59
- Revenue Per Employee
- 0
- Profits Per Employee
- -10.86M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Infant Bacterial Therapeutics AB is -10.79. Infant Bacterial Therapeutics AB’s PEG ratio is -0.97.
- PE Ratio
- -10.79
- PS Ratio
- 0.00
- PB Ratio
- 16.69
- Price to FCF
- -13.82
- Price to Operating Cash Flow
- -13.82
- PEG Ratio
- -0.97
Income Statement
In the last 12 months, Infant Bacterial Therapeutics AB had revenue of 0 and earned -65.17M in profits. Earnings per share was -4.84.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -61.95M
- Pretax Income
- -65.17M
- Net Income
- -65.17M
- EBITDA
- -68.18M
- Earnings Per Share (EPS)
- -4.84
Cash Flow
In the last 12 months, operating cash flow was -64.06M and capital expenditures 0, giving a free cash flow of -64.06M billion.
- Operating Cash Flow
- -64.06M
- Free Cash Flow
- -64.06M
- Free Cash Flow per Share
- -4.76
Dividends & Yields
Infant Bacterial Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.24%
- Earnings Yield
- -9.26%
Stock Price Statistics
- Beta
- -0.23
- 52-Week Price Change
- 13.36%
- 50-Day Moving Average
- 6.16
- 200-Day Moving Average
- 5.42
- Relative Strength Index (RSI)
- 40.22
- Average Volume (3m)
- 510
Important Dates
Infant Bacterial Therapeutics AB upcoming earnings date is Nov 13, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
Infant Bacterial Therapeutics AB as a current ratio of 2.72, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.72
- Quick Ratio
- 2.72
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.11
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Infant Bacterial Therapeutics AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Infant Bacterial Therapeutics AB EV to EBITDA ratio is -9.47, with an EV/FCF ratio of -12.12.
- EV to Sales
- 0.00
- EV to EBITDA
- -9.47
- EV to Free Cash Flow
- -12.12
- EV to Operating Cash Flow
- -12.12
Balance Sheet
Infant Bacterial Therapeutics AB has EUR 108.60M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 108.60M billion.
- Cash & Marketable Securities
- EUR 108.60M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 108.60M
- Net Cash Per Share
- EUR 8.34
- Tangible Book Value Per Share
- EUR 3.37
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Infant Bacterial Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 16.55%